Summit Trail Advisors LLC Has $300,000 Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Summit Trail Advisors LLC reduced its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 21.9% in the fourth quarter, HoldingsChannel reports. The firm owned 3,128 shares of the company’s stock after selling 876 shares during the period. Summit Trail Advisors LLC’s holdings in HealthEquity were worth $300,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. UMB Bank n.a. grew its stake in shares of HealthEquity by 65.6% in the 4th quarter. UMB Bank n.a. now owns 414 shares of the company’s stock valued at $40,000 after buying an additional 164 shares during the period. GAMMA Investing LLC boosted its holdings in HealthEquity by 57.8% in the third quarter. GAMMA Investing LLC now owns 939 shares of the company’s stock worth $77,000 after acquiring an additional 344 shares in the last quarter. Quarry LP grew its stake in HealthEquity by 418.8% in the third quarter. Quarry LP now owns 1,349 shares of the company’s stock valued at $110,000 after acquiring an additional 1,089 shares during the period. 1620 Investment Advisors Inc. acquired a new stake in HealthEquity in the third quarter valued at approximately $112,000. Finally, Covestor Ltd increased its holdings in shares of HealthEquity by 27.4% during the third quarter. Covestor Ltd now owns 1,524 shares of the company’s stock valued at $125,000 after acquiring an additional 328 shares in the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.

HealthEquity Price Performance

HealthEquity stock opened at $114.51 on Thursday. HealthEquity, Inc. has a 52 week low of $65.01 and a 52 week high of $114.69. The company’s 50 day moving average price is $101.63 and its two-hundred day moving average price is $90.37. The stock has a market cap of $9.92 billion, a P/E ratio of 105.06, a P/E/G ratio of 1.61 and a beta of 0.55. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Monday, December 9th. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period in the previous year, the company earned $0.40 EPS. On average, equities analysts predict that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

Insider Transactions at HealthEquity

In other news, Director Stuart B. Parker sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total transaction of $2,418,000.00. Following the completion of the transaction, the director now directly owns 19,061 shares of the company’s stock, valued at $1,843,579.92. This represents a 56.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the sale, the director now owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,000 shares of company stock worth $3,895,788 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on HQY. Barrington Research increased their target price on HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. JMP Securities upped their price objective on shares of HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a report on Tuesday, December 10th. The Goldman Sachs Group initiated coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 price objective on the stock. BTIG Research boosted their target price on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Finally, Royal Bank of Canada raised their price target on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.71.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.